ID   BCR_HUMAN               Reviewed;        1271 AA.
AC   P11274; P78501; Q12842; Q4LE80; Q6NZI3;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 2.
DT   10-MAY-2017, entry version 204.
DE   RecName: Full=Breakpoint cluster region protein;
DE            EC=2.7.11.1;
DE   AltName: Full=Renal carcinoma antigen NY-REN-26;
GN   Name=BCR; Synonyms=BCR1, D22S11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT SER-796.
RX   PubMed=3285291;
RA   Lifshitz B., Fainstein E., Marcelle C., Shtivelman E., Amson R.,
RA   Gale R.P., Canaani E.;
RT   "bcr genes and transcripts.";
RL   Oncogene 2:113-117(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND CHROMOSOMAL TRANSLOCATION.
RX   PubMed=7665185; DOI=10.1006/geno.1995.1008;
RA   Chissoe S.L., Bodenteich A., Wang Y.-F., Wang Y.-P., Burian D.,
RA   Clifton S.W., Crabtree J., Freeman A., Iyer K., Jian L., Ma Y.,
RA   McLaury H.-J., Pan H.-Q., Sarhan O.H., Toth S., Wang Z., Zhang G.,
RA   Heisterkamp N., Groffen J., Roe B.A.;
RT   "Sequence and analysis of the human ABL gene, the BCR gene, and
RT   regions involved in the Philadelphia chromosomal translocation.";
RL   Genomics 27:67-82(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   SER-796.
RC   TISSUE=Brain;
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M.,
RA   Ohara R., Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long
RT   cDNAs encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-872, CHROMOSOMAL TRANSLOCATION,
RP   INVOLVEMENT IN CML, AND VARIANT SER-796.
RX   PubMed=3107980;
RA   Hariharan I.K., Adams J.M.;
RT   "cDNA sequence for human bcr, the gene that translocates to the abl
RT   oncogene in chronic myeloid leukaemia.";
RL   EMBO J. 6:115-119(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-693, AND INVOLVEMENT IN CML.
RX   PubMed=3540951; DOI=10.1073/pnas.83.24.9768;
RA   Mes-Masson A.-M., McLaughlin J., Daley G.Q., Paskind M., Witte O.N.;
RT   "Overlapping cDNA clones define the complete coding region for the
RT   P210c-abl gene product associated with chronic myelogenous leukemia
RT   cells containing the Philadelphia chromosome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:9768-9772(1986).
RN   [6]
RP   ERRATUM, AND SEQUENCE REVISION.
RA   Mes-Masson A.M., McLaughlin J., Daley G.Q., Paskind M., Witte O.N.;
RL   Proc. Natl. Acad. Sci. U.S.A. 84:2507-2507(1987).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 683-1271 (ISOFORM 1).
RX   PubMed=2989703; DOI=10.1038/315758a0;
RA   Heisterkamp N., Stam K., Groffen J., de Klein A., Grosveld G.;
RT   "Structural organization of the bcr gene and its role in the Ph'
RT   translocation.";
RL   Nature 315:758-761(1985).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-46 AND 275-426.
RX   PubMed=2263470; DOI=10.1093/nar/18.23.7119;
RA   Zhu Q.S., Heisterkamp N., Groffen J.;
RT   "Unique organization of the human BCR gene promoter.";
RL   Nucleic Acids Res. 18:7119-7125(1990).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 56-426.
RX   PubMed=2825022; DOI=10.1038/330386a0;
RA   Fainstein E., Marcelle C., Rosner A., Canaani E., Gale R.P.,
RA   Dreazen O., Smith S.D., Croce C.M.;
RT   "A new fused transcript in Philadelphia chromosome positive acute
RT   lymphocytic leukaemia.";
RL   Nature 330:386-388(1987).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 362-438, AND ALTERNATIVE SPLICING.
RX   PubMed=2915904;
RA   Romero P., Beran M., Shtalrid M., Andersson B., Talpaz M., Blick M.;
RT   "Alternative 5' end of the bcr-abl transcript in chronic myelogenous
RT   leukemia.";
RL   Oncogene 4:93-98(1989).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 670-842, INVOLVEMENT IN CML, AND
RP   VARIANT SER-796.
RX   PubMed=2407300;
RA   Selleri L., von Lindern M., Hermans A., Meijer D., Torelli G.,
RA   Grosveld G.;
RT   "Chronic myeloid leukemia may be associated with several bcr-abl
RT   transcripts including the acute lymphoid leukemia-type 7 kb
RT   transcript.";
RL   Blood 75:1146-1153(1990).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-4.
RX   PubMed=1900918; DOI=10.1128/MCB.11.4.1854;
RA   Shah N.P., Witte O.N., Denny C.T.;
RT   "Characterization of the BCR promoter in Philadelphia chromosome-
RT   positive and -negative cell lines.";
RL   Mol. Cell. Biol. 11:1854-1860(1991).
RN   [13]
RP   FUNCTION.
RX   PubMed=1903516; DOI=10.1038/351400a0;
RA   Diekmann D., Brill S., Garrett M.D., Totty N., Hsuan J., Monfries C.,
RA   Hall C., Lim L., Hall A.;
RT   "Bcr encodes a GTPase-activating protein for p21rac.";
RL   Nature 351:400-402(1991).
RN   [14]
RP   INTERACTION WITH ABL1 SH2-DOMAIN.
RX   PubMed=1712671; DOI=10.1016/0092-8674(91)90148-R;
RA   Pendergast A.M., Muller A.J., Havlik M.H., Maru Y., Witte O.N.;
RT   "BCR sequences essential for transformation by the BCR-ABL oncogene
RT   bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-
RT   dependent manner.";
RL   Cell 66:161-171(1991).
RN   [15]
RP   FUNCTION AS PROTEIN KINASE.
RX   PubMed=1657398; DOI=10.1016/0092-8674(91)90521-Y;
RA   Maru Y., Witte O.N.;
RT   "The BCR gene encodes a novel serine/threonine kinase activity within
RT   a single exon.";
RL   Cell 67:459-468(1991).
RN   [16]
RP   PHOSPHORYLATION AT TYR-177 BY HCK, MUTAGENESIS OF TYR-177, AND
RP   INTERACTION WITH HCK AND GRB2.
RX   PubMed=9407116; DOI=10.1074/jbc.272.52.33260;
RA   Warmuth M., Bergmann M., Priess A., Hauslmann K., Emmerich B.,
RA   Hallek M.;
RT   "The Src family kinase Hck interacts with Bcr-Abl by a kinase-
RT   independent mechanism and phosphorylates the Grb2-binding site of
RT   Bcr.";
RL   J. Biol. Chem. 272:33260-33270(1997).
RN   [17]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-
RT   cell carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1264, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [19]
RP   INTERACTION WITH FES/FPS; ABL1; PIK3R1 AND GRB2, MUTAGENESIS OF
RP   TYR-177, AND PHOSPHORYLATION AT TYR-246.
RX   PubMed=15302586; DOI=10.1016/j.yexcr.2004.05.010;
RA   Laurent C.E., Smithgall T.E.;
RT   "The c-Fes tyrosine kinase cooperates with the breakpoint cluster
RT   region protein (Bcr) to induce neurite extension in a Rac- and Cdc42-
RT   dependent manner.";
RL   Exp. Cell Res. 299:188-198(2004).
RN   [20]
RP   INTERACTION WITH PDZK1, AND MUTAGENESIS OF 1269-THR--GLU-1271 AND
RP   VAL-1271.
RX   PubMed=15494376; DOI=10.1242/jcs.01472;
RA   Malmberg E.K., Andersson C.X., Gentzsch M., Chen J.H., Mengos A.,
RA   Cui L., Hansson G.C., Riordan J.R.;
RT   "Bcr (breakpoint cluster region) protein binds to PDZ-domains of
RT   scaffold protein PDZK1 and vesicle coat protein Mint3.";
RL   J. Cell Sci. 117:5535-5541(2004).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-459, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-177; SER-459 AND
RP   SER-1264, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-122; SER-215 AND
RP   SER-459, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [27]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-122; SER-139; SER-202;
RP   SER-215; SER-222; SER-356; SER-377; SER-459; SER-463; SER-473;
RP   SER-488; TYR-554; THR-641; TYR-644; THR-693 AND SER-894, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-459, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 3-72, AND
RP   HOMOTETRAMERIZATION.
RX   PubMed=11780146; DOI=10.1038/nsb747;
RA   Zhao X., Ghaffari S., Lodish H., Malashkevich V.N., Kim P.S.;
RT   "Structure of the Bcr-Abl oncoprotein oligomerization domain.";
RL   Nat. Struct. Biol. 9:117-120(2002).
RN   [31]
RP   INTERACTION WITH SH2D5.
RX   PubMed=25331951; DOI=10.1074/jbc.M114.615112;
RA   Gray E.J., Petsalaki E., James D.A., Bagshaw R.D., Stacey M.M.,
RA   Rocks O., Gingras A.C., Pawson T.;
RT   "src homology 2 domain containing protein 5 (sh2d5) binds the
RT   breakpoint cluster region protein, BCR, and regulates levels of Rac1-
RT   GTP.";
RL   J. Biol. Chem. 289:35397-35408(2014).
RN   [32]
RP   VARIANTS [LARGE SCALE ANALYSIS] PRO-400; MET-413; GLU-752; SER-796;
RP   CYS-910; ILE-949; LYS-1037; MET-1091; ALA-1096; GLY-1104; ASN-1106;
RP   THR-1149; LYS-1161; GLU-1187; MET-1189; GLY-1204 AND ARG-1235.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: GTPase-activating protein for RAC1 and CDC42. Promotes
CC       the exchange of RAC or CDC42-bound GDP by GTP, thereby activating
CC       them. Displays serine/threonine kinase activity.
CC       {ECO:0000269|PubMed:1657398, ECO:0000269|PubMed:1903516}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Homotetramer. Interacts with PDZK1. May interact with
CC       CCPG1 (By similarity). Interacts with FES/FPS, ABL1, PIK3R1 and
CC       GRB2. Interacts with HCK. Interacts with SH2D5 (PubMed:25331951).
CC       {ECO:0000250|UniProtKB:Q6PAJ1, ECO:0000269|PubMed:15302586,
CC       ECO:0000269|PubMed:15494376, ECO:0000269|PubMed:1712671,
CC       ECO:0000269|PubMed:25331951, ECO:0000269|PubMed:9407116}.
CC   -!- INTERACTION:
CC       P62993:GRB2; NbExp=8; IntAct=EBI-712838, EBI-401755;
CC       P18031:PTPN1; NbExp=3; IntAct=EBI-8658094, EBI-968788;
CC       Q9H2K2:TNKS2; NbExp=3; IntAct=EBI-712838, EBI-4398527;
CC       P04637:TP53; NbExp=2; IntAct=EBI-712838, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Cell junction, synapse, postsynaptic cell
CC       membrane, postsynaptic density {ECO:0000250|UniProtKB:Q6PAJ1}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P11274-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P11274-2; Sequence=VSP_024352;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The region involved in binding to ABL1 SH2-domain is rich
CC       in serine residues and needs to be Ser/Thr phosphorylated prior to
CC       SH2 binding. This region is essential for the activation of the
CC       ABL1 tyrosine kinase and transforming potential of the chimeric
CC       BCR-ABL oncogene.
CC   -!- DOMAIN: The DH domain is involved in interaction with CCPG1.
CC       {ECO:0000250}.
CC   -!- PTM: Autophosphorylated. Phosphorylated by FES/FPS on tyrosine
CC       residues, leading to down-regulation of the BCR kinase activity.
CC       Phosphorylation at Tyr-177 by HCK is important for interaction
CC       with GRB2. {ECO:0000269|PubMed:15302586,
CC       ECO:0000269|PubMed:9407116}.
CC   -!- DISEASE: Leukemia, chronic myeloid (CML) [MIM:608232]: A clonal
CC       myeloproliferative disorder of a pluripotent stem cell with a
CC       specific cytogenetic abnormality, the Philadelphia chromosome
CC       (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid,
CC       and sometimes T-lymphoid cells, but not marrow fibroblasts.
CC       {ECO:0000269|PubMed:2407300, ECO:0000269|PubMed:3107980,
CC       ECO:0000269|PubMed:3540951}. Note=The gene represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- DISEASE: Note=A chromosomal aberration involving BCR has been
CC       found in patients with chronic myeloid leukemia. Translocation
CC       t(9;22)(q34;q11) with ABL1. The translocation produces a BCR-ABL
CC       found also in acute myeloid leukemia (AML) and acute lymphoblastic
CC       leukemia (ALL). {ECO:0000269|PubMed:3107980,
CC       ECO:0000269|PubMed:7665185}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAE06073.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BCRID55.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00661; CAA68676.1; -; mRNA.
DR   EMBL; U07000; AAB60388.1; -; Genomic_DNA.
DR   EMBL; AB209991; BAE06073.1; ALT_INIT; mRNA.
DR   EMBL; X02596; CAA26441.1; -; mRNA.
DR   EMBL; M15025; AAA35594.1; -; Genomic_DNA.
DR   EMBL; X52828; CAA37010.1; -; Genomic_DNA.
DR   EMBL; X52829; CAA37011.1; -; Genomic_DNA.
DR   EMBL; X14676; CAA32806.1; -; mRNA.
DR   EMBL; M64437; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS13806.1; -. [P11274-1]
DR   CCDS; CCDS13807.1; -. [P11274-2]
DR   PIR; A26664; TVHUA2.
DR   PIR; A91064; TVHUBR.
DR   RefSeq; NP_004318.3; NM_004327.3. [P11274-1]
DR   RefSeq; NP_067585.2; NM_021574.2. [P11274-2]
DR   UniGene; Hs.517461; -.
DR   UniGene; Hs.715409; -.
DR   PDB; 1K1F; X-ray; 2.20 A; A/B/C/D/E/F/G/H=1-72.
DR   PDB; 2AIN; NMR; -; B=1266-1271.
DR   PDBsum; 1K1F; -.
DR   PDBsum; 2AIN; -.
DR   ProteinModelPortal; P11274; -.
DR   SMR; P11274; -.
DR   BioGrid; 107083; 64.
DR   IntAct; P11274; 29.
DR   MINT; MINT-1207264; -.
DR   STRING; 9606.ENSP00000303507; -.
DR   BindingDB; P11274; -.
DR   ChEMBL; CHEMBL5146; -.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB08901; Ponatinib.
DR   iPTMnet; P11274; -.
DR   PhosphoSitePlus; P11274; -.
DR   BioMuta; BCR; -.
DR   DMDM; 143811366; -.
DR   EPD; P11274; -.
DR   MaxQB; P11274; -.
DR   PaxDb; P11274; -.
DR   PeptideAtlas; P11274; -.
DR   PRIDE; P11274; -.
DR   Ensembl; ENST00000305877; ENSP00000303507; ENSG00000186716. [P11274-1]
DR   Ensembl; ENST00000359540; ENSP00000352535; ENSG00000186716. [P11274-2]
DR   GeneID; 613; -.
DR   KEGG; hsa:613; -.
DR   UCSC; uc002zww.4; human. [P11274-1]
DR   CTD; 613; -.
DR   DisGeNET; 613; -.
DR   GeneCards; BCR; -.
DR   H-InvDB; HIX0016226; -.
DR   H-InvDB; HIX0016271; -.
DR   H-InvDB; HIX0027936; -.
DR   H-InvDB; HIX0041406; -.
DR   HGNC; HGNC:1014; BCR.
DR   HPA; CAB010421; -.
DR   HPA; CAB018545; -.
DR   HPA; HPA038337; -.
DR   MalaCards; BCR; -.
DR   MIM; 151410; gene.
DR   MIM; 608232; phenotype.
DR   neXtProt; NX_P11274; -.
DR   OpenTargets; ENSG00000186716; -.
DR   Orphanet; 521; Chronic myeloid leukemia.
DR   Orphanet; 261330; Distal 22q11.2 microdeletion syndrome.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   Orphanet; 99861; Precursor T-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA25321; -.
DR   eggNOG; KOG4269; Eukaryota.
DR   eggNOG; ENOG410XPGZ; LUCA.
DR   GeneTree; ENSGT00860000133689; -.
DR   HOGENOM; HOG000006779; -.
DR   HOVERGEN; HBG004165; -.
DR   InParanoid; P11274; -.
DR   KO; K08878; -.
DR   OMA; VGGMMVE; -.
DR   OrthoDB; EOG091G03M3; -.
DR   PhylomeDB; P11274; -.
DR   TreeFam; TF105082; -.
DR   Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants.
DR   Reactome; R-HSA-194840; Rho GTPase cycle.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   SignaLink; P11274; -.
DR   SIGNOR; P11274; -.
DR   ChiTaRS; BCR; human.
DR   EvolutionaryTrace; P11274; -.
DR   GeneWiki; BCR_(gene); -.
DR   GenomeRNAi; 613; -.
DR   PRO; PR:P11274; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000186716; -.
DR   CleanEx; HS_BCR; -.
DR   ExpressionAtlas; P11274; baseline and differential.
DR   Genevisible; P11274; HS.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; ISS:UniProtKB.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IEA:Ensembl.
DR   GO; GO:0005096; F:GTPase activator activity; IBA:GO_Central.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0005089; F:Rho guanyl-nucleotide exchange factor activity; IEA:InterPro.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0060216; P:definitive hemopoiesis; IEA:Ensembl.
DR   GO; GO:0048872; P:homeostasis of number of cells; IEA:Ensembl.
DR   GO; GO:0042472; P:inner ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0065002; P:intracellular protein transmembrane transport; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0060313; P:negative regulation of blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0002692; P:negative regulation of cellular extravasation; IEA:Ensembl.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0043314; P:negative regulation of neutrophil degranulation; IEA:Ensembl.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0060268; P:negative regulation of respiratory burst; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IBA:GO_Central.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0051726; P:regulation of cell cycle; IEA:Ensembl.
DR   GO; GO:0051171; P:regulation of nitrogen compound metabolic process; IEA:Ensembl.
DR   GO; GO:0035023; P:regulation of Rho protein signal transduction; IEA:InterPro.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0043114; P:regulation of vascular permeability; IEA:Ensembl.
DR   GO; GO:0003014; P:renal system process; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR015123; Bcr-Abl_oncoprot_oligo.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR000219; DH-domain.
DR   InterPro; IPR001331; GDS_CDC24_CS.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR008936; Rho_GTPase_activation_prot.
DR   InterPro; IPR000198; RhoGAP_dom.
DR   Pfam; PF09036; Bcr-Abl_Oligo; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00620; RhoGAP; 1.
DR   Pfam; PF00621; RhoGEF; 1.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00324; RhoGAP; 1.
DR   SMART; SM00325; RhoGEF; 1.
DR   SUPFAM; SSF48065; SSF48065; 1.
DR   SUPFAM; SSF48350; SSF48350; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF50729; SSF50729; 2.
DR   SUPFAM; SSF69036; SSF69036; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00741; DH_1; 1.
DR   PROSITE; PS50010; DH_2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50238; RHOGAP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell junction; Cell membrane; Chromosomal rearrangement;
KW   Complete proteome; GTPase activation;
KW   Guanine-nucleotide releasing factor; Kinase; Membrane; Methylation;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Postsynaptic cell membrane; Proto-oncogene; Reference proteome;
KW   Serine/threonine-protein kinase; Synapse; Transferase.
FT   CHAIN         1   1271       Breakpoint cluster region protein.
FT                                /FTId=PRO_0000080933.
FT   DOMAIN      498    691       DH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00062}.
FT   DOMAIN      708    866       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      870   1002       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   DOMAIN     1054   1248       Rho-GAP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00172}.
FT   REGION        1    426       Kinase.
FT   REGION      197    385       Binding to ABL SH2-domain.
FT   COMPBIAS    824    827       Poly-Leu.
FT   SITE        426    427       Breakpoint for translocation to form BCR-
FT                                ABL oncogene.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:22223895}.
FT   MOD_RES     122    122       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     139    139       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     177    177       Phosphotyrosine; by HCK.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:9407116}.
FT   MOD_RES     202    202       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     215    215       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     222    222       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     236    236       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6PAJ1}.
FT   MOD_RES     246    246       Phosphotyrosine; by FES.
FT                                {ECO:0000269|PubMed:15302586}.
FT   MOD_RES     356    356       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     377    377       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     382    382       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6PAJ1}.
FT   MOD_RES     385    385       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q6PAJ1}.
FT   MOD_RES     459    459       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     463    463       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     471    471       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:Q6PAJ1}.
FT   MOD_RES     473    473       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     488    488       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     554    554       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     641    641       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     644    644       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     693    693       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     894    894       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1264   1264       Phosphoserine.
FT                                {ECO:0000244|PubMed:15144186,
FT                                ECO:0000244|PubMed:19690332}.
FT   VAR_SEQ     961   1004       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:3285291}.
FT                                /FTId=VSP_024352.
FT   VARIANT     400    400       S -> P (in a bladder transitional cell
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041883.
FT   VARIANT     413    413       I -> M (in dbSNP:rs56321828).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041884.
FT   VARIANT     558    558       K -> T (in dbSNP:rs4437065).
FT                                /FTId=VAR_051983.
FT   VARIANT     752    752       D -> E (in dbSNP:rs12484731).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041885.
FT   VARIANT     796    796       N -> S (in dbSNP:rs140504).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:2407300,
FT                                ECO:0000269|PubMed:3107980,
FT                                ECO:0000269|PubMed:3285291,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_031552.
FT   VARIANT     910    910       Y -> C (in dbSNP:rs35537221).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041886.
FT   VARIANT     949    949       V -> I (in dbSNP:rs2229038).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041887.
FT   VARIANT    1037   1037       E -> K (in dbSNP:rs16999516).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_031553.
FT   VARIANT    1091   1091       V -> M (in dbSNP:rs778229520).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041888.
FT   VARIANT    1096   1096       T -> A (in dbSNP:rs745459086).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041889.
FT   VARIANT    1104   1104       A -> G (in dbSNP:rs11558696).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041890.
FT   VARIANT    1106   1106       D -> N. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041891.
FT   VARIANT    1127   1127       T -> M (in dbSNP:rs35812689).
FT                                /FTId=VAR_031554.
FT   VARIANT    1149   1149       A -> T (in dbSNP:rs200099830).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041892.
FT   VARIANT    1161   1161       E -> K. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041893.
FT   VARIANT    1187   1187       K -> E. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041894.
FT   VARIANT    1189   1189       V -> M (in dbSNP:rs55816482).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041895.
FT   VARIANT    1204   1204       A -> G (in dbSNP:rs56265970).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041896.
FT   VARIANT    1235   1235       W -> R (in dbSNP:rs55719322).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041897.
FT   MUTAGEN     177    177       Y->F: Abolishes interaction with FES and
FT                                GRB2. {ECO:0000269|PubMed:15302586,
FT                                ECO:0000269|PubMed:9407116}.
FT   MUTAGEN    1269   1271       Missing: Abolishes interaction with
FT                                PDZK1. {ECO:0000269|PubMed:15494376}.
FT   MUTAGEN    1271   1271       V->A: Reduces interaction with PDZK1.
FT                                {ECO:0000269|PubMed:15494376}.
FT   CONFLICT    287    287       M -> I (in Ref. 1; CAA68676).
FT                                {ECO:0000305}.
FT   CONFLICT    418    418       G -> D (in Ref. 1; CAA68676).
FT                                {ECO:0000305}.
FT   CONFLICT    483    483       E -> K (in Ref. 1; CAA68676).
FT                                {ECO:0000305}.
FT   CONFLICT    560    560       F -> S (in Ref. 1; CAA68676).
FT                                {ECO:0000305}.
FT   CONFLICT    690    690       E -> D (in Ref. 11). {ECO:0000305}.
FT   CONFLICT    733    733       D -> E (in Ref. 4; CAA26441).
FT                                {ECO:0000305}.
FT   HELIX         4     14       {ECO:0000244|PDB:1K1F}.
FT   HELIX        28     64       {ECO:0000244|PDB:1K1F}.
FT   STRAND     1268   1271       {ECO:0000244|PDB:2AIN}.
SQ   SEQUENCE   1271 AA;  142819 MW;  4BF66FA1E9D205FE CRC64;
     MVDPVGFAEA WKAQFPDSEP PRMELRSVGD IEQELERCKA SIRRLEQEVN QERFRMIYLQ
     TLLAKEKKSY DRQRWGFRRA AQAPDGASEP RASASRPQPA PADGADPPPA EEPEARPDGE
     GSPGKARPGT ARRPGAAASG ERDDRGPPAS VAALRSNFER IRKGHGQPGA DAEKPFYVNV
     EFHHERGLVK VNDKEVSDRI SSLGSQAMQM ERKKSQHGAG SSVGDASRPP YRGRSSESSC
     GVDGDYEDAE LNPRFLKDNL IDANGGSRPP WPPLEYQPYQ SIYVGGMMEG EGKGPLLRSQ
     STSEQEKRLT WPRRSYSPRS FEDCGGGYTP DCSSNENLTS SEEDFSSGQS SRVSPSPTTY
     RMFRDKSRSP SQNSQQSFDS SSPPTPQCHK RHRHCPVVVS EATIVGVRKT GQIWPNDGEG
     AFHGDADGSF GTPPGYGCAA DRAEEQRRHQ DGLPYIDDSP SSSPHLSSKG RGSRDALVSG
     ALESTKASEL DLEKGLEMRK WVLSGILASE ETYLSHLEAL LLPMKPLKAA ATTSQPVLTS
     QQIETIFFKV PELYEIHKEF YDGLFPRVQQ WSHQQRVGDL FQKLASQLGV YRAFVDNYGV
     AMEMAEKCCQ ANAQFAEISE NLRARSNKDA KDPTTKNSLE TLLYKPVDRV TRSTLVLHDL
     LKHTPASHPD HPLLQDALRI SQNFLSSINE EITPRRQSMT VKKGEHRQLL KDSFMVELVE
     GARKLRHVFL FTDLLLCTKL KKQSGGKTQQ YDCKWYIPLT DLSFQMVDEL EAVPNIPLVP
     DEELDALKIK ISQIKNDIQR EKRANKGSKA TERLKKKLSE QESLLLLMSP SMAFRVHSRN
     GKSYTFLISS DYERAEWREN IREQQKKCFR SFSLTSVELQ MLTNSCVKLQ TVHSIPLTIN
     KEDDESPGLY GFLNVIVHSA TGFKQSSNLY CTLEVDSFGY FVNKAKTRVY RDTAEPNWNE
     EFEIELEGSQ TLRILCYEKC YNKTKIPKED GESTDRLMGK GQVQLDPQAL QDRDWQRTVI
     AMNGIEVKLS VKFNSREFSL KRMPSRKQTG VFGVKIAVVT KRERSKVPYI VRQCVEEIER
     RGMEEVGIYR VSGVATDIQA LKAAFDVNNK DVSVMMSEMD VNAIAGTLKL YFRELPEPLF
     TDEFYPNFAE GIALSDPVAK ESCMLNLLLS LPEANLLTFL FLLDHLKRVA EKEAVNKMSL
     HNLATVFGPT LLRPSEKESK LPANPSQPIT MTDSWSLEVM SQVQVLLYFL QLEAIPAPDS
     KRQSILFSTE V
//
